Preparation and in vitro studies of [125I]IUDR-T101 antibody conjugate.
Idoxuridine labeled with 125I was conjugated to polylysine. This conjugate was then coupled to the carbohydrate side chains of T101 monoclonal antibody (anti-CD5). The immunoreactivity, cell retention, cytotoxicity, and intracellular localization of this conjugate was tested in CCRF-CEM cells (CD5 positive). The conjugate had 68% immunoreactivity. The retention of 125I by CCRF-CEM cells was higher for the conjugate than for T101 directly labeled with 125I and more of it localized in the nucleus than did the 125I-labeled T101. The 125I IUDR-polylysine-T101 conjugate was more cytotoxic than the 125I-labeled T101. In conclusion, the conjugation of [125I]IUDR to T101 is feasible, and preferential targeting of the 125I to the nucleus is obtained.
Chakrabarti
M C
MC
Department of Nuclear Medicine, Warren G. Magnuson Clinical Center, National Institute of Health, Bethesda, Maryland 20892-1180, USA.
Paik
C H
CH
Carrasquillo
J A
JA
D000911:Antibodies, Monoclonal / Q000276:immunology; D018956:CD5 Antigens / Q000276:immunology; D006801:Humans; D007065:Idoxuridine / Q000032:analysis / Q000378:metabolism* / Q000633:toxicity; D018796:Immunoconjugates / Q000032:analysis / Q000302:isolation & purification / Q000378:metabolism* / Q000633:toxicity; D007457:Iodine Radioisotopes / Q000032:analysis / Q000378:metabolism* / Q000633:toxicity; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000473:pathology; D011107:Polylysine / Q000378:metabolism; D013347:Subcellular Fractions / Q000737:chemistry; D013601:T-Lymphocytes / Q000378:metabolism* / Q000528:radiation effects; D014407:Tumor Cells, Cultured / Q000378:metabolism / Q000528:radiation effects
D000911:Antibodies, Monoclonal; D018956:CD5 Antigens; D018796:Immunoconjugates; D007457:Iodine Radioisotopes; D011107:Polylysine; D007065:Idoxuridine